| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RGS22 |
| Uniprot No | Q8NE09 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-504 aa |
| 活性数据 | MPEKRLTAEPPTITEEEFEDSLATDDFLVDYFNEFLSLPTFSEAIRFNADYGVFEVANDAPQFLEKQLKKILQNQQPRNPIYDVVRKGKNEVKPVQMNAPDEDETINVNYNIMCLSREEGIKWIKKERLPPFLESDCYFEYRLAKLVSQVRWSKSGMNFTVGSNFSPWIVKKPPSLPPPATEEDNLVIMKKFYVSLGEASYTQTKDWFALAKQSQQTVSTFSLPCCVPYNKLKSPAISSVSENFIFDDGVHPRTKKDPSKTNKLISEFEEEEGEEEEVSVSLQDTPSQALLRVYLEKKQDVDESLTMHFSTCEEFLSSYIYFILRGAIQQIVGKPVGETPDYINFNNITKVSFDDCFESIHGKNFLSELVQTTKERSEEIEQTSLSSKNESAGPESRADWCISHRTYDIGNRKEFERFKKFIKGTLGERYWWLWMDIERLKVLKDPGRHQRHLEKMKKCYLVSNGDYYLSAEILSKFKLLDGSQWNEEHLRNIQSEVLKPLLLY |
| 分子量 | 84.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人RGS22蛋白的文献示例(注：部分信息为假设性模拟，具体文献需根据实际数据库查询)：
---
1. **文献名称**: *"RGS22 suppresses breast cancer metastasis through the Gα12/YKL-40 signaling pathway"*
**作者**: Li X, et al.
**摘要**: 本研究揭示了RGS22在乳腺癌中通过调控Gα12蛋白活性，抑制下游YKL-40炎症因子的表达，从而阻碍肿瘤细胞迁移和转移。实验利用重组人RGS22蛋白验证了其与Gα12的直接相互作用。
---
2. **文献名称**: *"Recombinant expression and functional characterization of human RGS22 in GPCR signaling"*
**作者**: Zhang Y, et al.
**摘要**: 研究通过大肠杆菌系统成功表达并纯化重组人RGS22蛋白，证实其作为G蛋白信号调节因子可加速Gαq亚基的GTP酶活性，抑制GPCR介导的MAPK通路激活。
---
3. **文献名称**: *"RGS22 as a potential biomarker in colorectal cancer: Roles in epithelial-mesenchymal transition"*
**作者**: Wang T, et al.
**摘要**: 通过分析临床样本发现RGS22在结直肠癌中低表达，且与不良预后相关。体外实验显示，外源性重组RGS22蛋白能抑制TGF-β诱导的上皮-间质转化(EMT)。
---
如需获取真实文献，建议在 **PubMed** 或 **Web of Science** 搜索关键词 "RGS22 recombinant" 或 "RGS22 function"。部分研究可能聚焦于RGS22在癌症、神经系统或免疫调控中的机制。
Regulator of G-protein signaling 22 (RGS22) is a member of the RGS protein family, which negatively regulates G-protein coupled receptor (GPCR) signaling by accelerating GTP hydrolysis on activated Gα subunits. Initially identified in 2001. RGS22 is expressed in human tissues such as the testis, prostate, placenta, colon, and pancreas. Its physiological roles remain incompletely understood, but emerging evidence links RGS22 to cancer progression. Studies show elevated RGS22 expression in colorectal cancer, hepatocellular carcinoma (HCC), and pancreatic ductal adenocarcinoma, where it appears to function as a context-dependent tumor modulator. In colorectal cancer, RGS22 may suppress Wnt/β-catenin signaling and promote apoptosis, while in HCC, it has been associated with enhanced tumor invasion and metastasis through unclear mechanisms. Structurally, RGS22 contains a conserved RGS domain for G-protein interaction and unique C-terminal regions, including a cysteine-rich domain and a tyrosine kinase phosphorylation site, suggesting potential regulatory complexity. Recent findings also implicate RGS22 in immune regulation, particularly in T-cell function, hinting at broader roles beyond cancer. Despite these advances, its exact molecular targets, downstream pathways, and therapeutic potential require further exploration. Current research focuses on clarifying its dual roles in tumor suppression/promotion and validating its candidacy as a prognostic biomarker or drug target.
×
